Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) PT at $16.25

Ocular Therapeutix, Inc. (NASDAQ:OCULGet Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $16.25.

A number of research firms recently issued reports on OCUL. Royal Bank Of Canada began coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an “outperform” rating and a $17.00 target price for the company. William Blair began coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an “outperform” rating for the company. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Finally, Needham & Company LLC decreased their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th.

Get Our Latest Analysis on OCUL

Insiders Place Their Bets

In related news, insider Pravin Dugel sold 21,219 shares of the company’s stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the transaction, the insider now owns 3,499,099 shares in the company, valued at $25,123,530.82. This represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard L. Md Lindstrom purchased 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the transaction, the director now owns 172,704 shares in the company, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 29,079 shares of company stock worth $208,739. Company insiders own 2.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in Ocular Therapeutix during the 4th quarter valued at about $1,722,000. Charles Schwab Investment Management Inc. grew its stake in Ocular Therapeutix by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock valued at $9,663,000 after acquiring an additional 21,025 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Ocular Therapeutix by 82.9% during the 4th quarter. Ameriprise Financial Inc. now owns 89,772 shares of the biopharmaceutical company’s stock valued at $767,000 after acquiring an additional 40,700 shares in the last quarter. ProShare Advisors LLC grew its stake in Ocular Therapeutix by 32.8% during the 4th quarter. ProShare Advisors LLC now owns 51,270 shares of the biopharmaceutical company’s stock valued at $438,000 after acquiring an additional 12,669 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in Ocular Therapeutix by 21.9% during the 4th quarter. Two Sigma Investments LP now owns 252,939 shares of the biopharmaceutical company’s stock valued at $2,160,000 after acquiring an additional 45,518 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Trading Down 5.1%

NASDAQ:OCUL opened at $8.30 on Friday. Ocular Therapeutix has a 12 month low of $5.34 and a 12 month high of $11.78. The firm has a fifty day simple moving average of $7.79 and a 200-day simple moving average of $7.86. The company has a current ratio of 10.22, a quick ratio of 10.14 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $1.32 billion, a P/E ratio of -7.22 and a beta of 1.42.

About Ocular Therapeutix

(Get Free Report

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Recommended Stories

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.